Pyxis Oncology, Inc., a biotechnology company operating within the health care sector, has been actively engaged in the development of innovative therapies aimed at addressing challenging cancer cases. As of October 8, 2025, the company’s stock was trading at a close price of $3.83 on the Nasdaq exchange. This valuation reflects a significant fluctuation over the past year, with the stock reaching a 52-week high of $5.39 on November 10, 2024, and a 52-week low of $0.833 on April 6, 2025. The market capitalization of Pyxis Oncology stands at approximately $237.53 million USD.

The company’s primary focus is on creating novel therapeutic solutions to aid patients battling difficult-to-treat cancers. Pyxis Oncology serves medical professionals across the United States, providing them with cutting-edge treatments designed to improve patient outcomes in oncology. The company’s commitment to innovation in cancer therapy underscores its role in the broader health care sector, where advancements in treatment options are critical for enhancing patient care.

Pyxis Oncology’s activities and developments can be further explored through their official website, www.pyxisoncology.com , where stakeholders and interested parties can access detailed information about the company’s ongoing projects and strategic initiatives. As a publicly traded entity on the Nasdaq, Pyxis Oncology remains subject to market dynamics and investor interest, which are reflected in its stock performance and market valuation.

In summary, Pyxis Oncology, Inc. continues to play a pivotal role in the biotechnology landscape by focusing on the development of novel cancer therapies. Its efforts to provide advanced treatment options for difficult-to-treat cancers highlight its commitment to improving patient care within the health care sector. The company’s financial metrics, including its market capitalization and stock performance, provide insight into its current standing and potential future trajectory in the competitive biotech industry.